glp 1 agonists reduce inflammation GLP-1 Drugs: For Multiple Chronic Conditions GLP-1 agonists' potential effects on

FDA labeling states that GLP-1 receptor agonists are not recommended for patients with severe gastroparesis

All Simple Peptide products are labeled Research Use Only (RUO) and are intended strictly for laboratory, investigational, and scientific research purposes

While this mechanism is highly effective for weight management and diabetes control, it creates a cascade of effects throughout your digestive system that can significantly impact your gut microbiome and overall digestive health

[DOI] [PubMed] [Google Scholar] 249.Kuhre R.E., Gribble F.M., Hartmann B., Reimann F., Windelov J.A., Rehfeld J.F

2021;4(1):e2033457

Contact your healthcare provider promptly if you experience: Persistent dizziness lasting more than a few seconds when standing Fainting or near-fainting episodes Falls or loss of balance attributed to dizziness Chest pain, palpitations, or irregular heartbeat accompanying low blood pressure symptoms Severe or persistent nausea, vomiting, or diarrhea leading to dehydration Confusion, difficulty concentrating, or unusual fatigue Blood pressure readings consistently below 90/60 mmHg with symptoms New or worsening shortness of breath Seek emergency care (call 911) if you experience: Loss of consciousness Chest pain or pressure Severe shortness of breath Confusion or altered mental status Seizures Signs of stroke (facial drooping, arm weakness, speech difficulty) Your healthcare provider may need to adjust your GLP-1 medication dose, modify or discontinue antihypertensive medications, or investigate other potential causes of hypotension